Literature DB >> 35133487

Quantitative analysis of branching neovascular networks in polypoidal choroidal vasculopathy by optical coherence tomography angiography after photodynamic therapy and anti-vascular endothelial growth factor combination therapy.

Wen-Yi Wang1, Chang-Hao Yang1,2, Ta-Ching Chen1,3, Yi-Ting Hsieh1,2, Tzyy-Chang Ho1,2, Chung-May Yang1,2, Fang-Yu Liu1,4, Tso-Ting Lai5,6.   

Abstract

PURPOSE: To study serial changes in branching neovascular networks (BNN) by using optical coherence tomography angiography (OCTA) in patients with polypoidal choroidal vasculopathy (PCV) who underwent combined photodynamic therapy (PDT) and anti-vascular endothelial growth factor (anti-VEGF) therapy.
METHODS: In this retrospective study of 30 PCV patients who underwent combined therapy, OCTA images obtained at baseline and 1, 3, and 6 months after treatment were collected. The vessel area, vessel percentage area, average vessel length, and presence of polypoidal lesions on OCTA images as well as best-corrected visual acuity (BCVA), central retinal thickness (CRT), and central choroidal thickness (CCT) were recorded at each time point.
RESULTS: The BNN- and polypoidal lesion-detection rates on baseline OCTA images were 100% and 71%, respectively. The vessel area decreased during the first 3 months, and increased 6 months post-treatment, showing significant differences from baseline (p = 0.031). The vessel percentage area also reduced 1 and 3 months post-treatment (p = 0.025) and increased 6 months post-treatment. Continuous polypoidal lesion regression was observed from 1 to 3 and 6 months post-treatment (p = 0.031, p = 0.004, p = 0.002, respectively, in comparison with baseline). Patients with a decreasing vessel area over 6 months showed greater choroidal thickness than those with increasing vessel area (p = 0.004).
CONCLUSIONS: The BNN showed initial regression but were enlarged at 6 months after therapy. Patients showing continuous BNN regression showed a thicker choroid at baseline. This difference should be considered during treatment for PCV, and OCTA could be used for follow-up evaluations of PCV patients.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Branching neovascular network; Optical coherence tomography angiography; Photodynamic therapy; Polypoidal choroidal vasculopathy

Mesh:

Substances:

Year:  2022        PMID: 35133487     DOI: 10.1007/s00417-022-05583-z

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  37 in total

1.  Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography.

Authors:  Richard F Spaide; James M Klancnik; Michael J Cooney
Journal:  JAMA Ophthalmol       Date:  2015-01       Impact factor: 7.389

2.  Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial.

Authors:  Won Ki Lee; Tomohiro Iida; Yuichiro Ogura; Shih-Jen Chen; Tien Yin Wong; Paul Mitchell; Gemmy Chui Ming Cheung; Zhongqi Zhang; Sérgio Leal; Tatsuro Ishibashi
Journal:  JAMA Ophthalmol       Date:  2018-07-01       Impact factor: 7.389

Review 3.  Management of polypoidal choroidal vasculopathy: Experts consensus in Taiwan.

Authors:  Lee-Jen Chen; Cheng-Kuo Cheng; Ling Yeung; Chang-Hao Yang; Shih-Jen Chen
Journal:  J Formos Med Assoc       Date:  2019-05-07       Impact factor: 3.282

4.  En face imaging of the choroid in polypoidal choroidal vasculopathy using swept-source optical coherence tomography.

Authors:  Tarek Alasil; Daniela Ferrara; Mehreen Adhi; Erika Brewer; Martin F Kraus; Caroline R Baumal; Joachim Hornegger; James G Fujimoto; Andre J Witkin; Elias Reichel; Jay S Duker; Nadia K Waheed
Journal:  Am J Ophthalmol       Date:  2014-12-19       Impact factor: 5.258

5.  Optical Coherence Tomography Angiography for Assessment of the 3-Dimensional Structures of Polypoidal Choroidal Vasculopathy.

Authors:  Yu-Tien Chi; Chang-Hao Yang; Cheng-Kuo Cheng
Journal:  JAMA Ophthalmol       Date:  2017-12-01       Impact factor: 7.389

Review 6.  Polypoidal choroidal vasculopathy: a review.

Authors:  Yutaka Imamura; Michael Engelbert; Tomohiro Iida; K Bailey Freund; Lawrence A Yannuzzi
Journal:  Surv Ophthalmol       Date:  2010-09-20       Impact factor: 6.048

7.  Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy.

Authors:  R F Spaide; L A Yannuzzi; J S Slakter; J Sorenson; D A Orlach
Journal:  Retina       Date:  1995       Impact factor: 4.256

8.  Polypoidal Choroidal Vasculopathy: Consensus Nomenclature and Non-Indocyanine Green Angiograph Diagnostic Criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup.

Authors:  Chui M Gemmy Cheung; Timothy Y Y Lai; Kelvin Teo; Paisan Ruamviboonsuk; Shih-Jen Chen; Judy E Kim; Fumi Gomi; Adrian H Koh; Gregg Kokame; Janice Marie Jordan-Yu; Federico Corvi; Alessandro Invernizzi; Yuichiro Ogura; Colin Tan; Paul Mitchell; Vishali Gupta; Jay Chhablani; Usha Chakravarthy; Srinivas R Sadda; Tien Y Wong; Giovanni Staurenghi; Won Ki Lee
Journal:  Ophthalmology       Date:  2020-08-11       Impact factor: 12.079

9.  Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.

Authors:  Adrian Koh; Timothy Y Y Lai; Kanji Takahashi; Tien Y Wong; Lee-Jen Chen; Paisan Ruamviboonsuk; Colin S Tan; Chrystel Feller; Philippe Margaron; Tock H Lim; Won Ki Lee
Journal:  JAMA Ophthalmol       Date:  2017-11-01       Impact factor: 7.389

Review 10.  Polypoidal choroidal vasculopathy: An update on current management and review of literature.

Authors:  Amit Harishchandra Palkar; Vikas Khetan
Journal:  Taiwan J Ophthalmol       Date:  2019 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.